Incidental gallbladder cancer (found after cholecystectomy)
Prepared with OnCo (onco.cc/prep/incidental-gallbladder-cancer/). Orientation, not medical advice; your team knows your case.
My details
What I know, what is unclear, changes to discuss
Saved in this browserMy questions
14 on the sheet- 1.What is my exact diagnosis, stage, and grade, and which tests established them?
- 2.Which biomarkers have been tested on my tumour (for example T category on the specimen, Cystic duct margin status, Whether the gallbladder was perforated or bile spilled at the first operation, Interval since cholecystectomy, Residual or distant disease on interval CT, MRI and PET-CT), and what were the results?
- 3.Which subtype is my cancer, and does that change the recommended treatment?
- 4.Is germline (inherited) genetic testing recommended for me or my family?
- 5.For my situation (tis or t1a with a clear cystic duct margin), which of the standard options do you recommend and why?
- 6.For my situation (t1b, t2 or t3, no metastases), which of the standard options do you recommend and why?
- 7.Am I a candidate for Capecitabine, and what side effects should I expect?
- 8.How do the results of BILCAP apply to someone like me?
- 9.For my situation (residual disease found on interval imaging or at re-operation), which of the standard options do you recommend and why?
- 10.Am I a candidate for Gemcitabine + cisplatin, Durvalumab, Pembrolizumab, and what side effects should I expect?
- 11.Would a second opinion at a high-volume centre change anything, and can you help arrange it?
- 12.What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?
- 13.I read that “Whether T1b tumours need re-resection: two 2024 to 2026 analyses disagree on disease-specific benefit”. How does that affect my plan?
- 14.I read that “How many UK patients with an incidental cancer reach a hepatobiliary centre is not published”. How does that affect my plan?
The words I may hear
- Port-site metastasis: Cancer growing in the small keyhole wounds of a laparoscopic operation, seeded when a gallbladder containing an unsuspected cancer was pulled out through them.
- Segment IVb and V liver resection (versus wedge resection): Two ways of removing the piece of liver the gallbladder sits on during a gallbladder cancer operation: a wedge of about two centimetres around the gallbladder bed, or the whole of the two anatomical liver segments (IVb and V) that touch it.
- Cystic duct margin: The cut end of the short duct that joined the gallbladder to the main bile duct, examined by the pathologist after a gallbladder is removed.
- Simple cholecystectomy: The standard operation to remove the gallbladder, almost always by keyhole surgery for gallstones.
- Radical (extended) cholecystectomy: The cancer operation for gallbladder cancer: the gallbladder (if still present) is removed together with a rim of the liver it sits against and the lymph nodes along the bile duct and liver blood vessels.
- Lymphadenectomy (lymph node dissection): Surgically removing the lymph nodes that drain a tumour, both to stage the cancer and to clear any spread.
Tests and results to bring
Biomarker results to ask for: T category on the specimen (the single decision-maker), Cystic duct margin status, Whether the gallbladder was perforated or bile spilled at the first operation, Interval since cholecystectomy (4 to 8 weeks target), Residual or distant disease on interval CT, MRI and PET-CT.
Scans and tests linked to this cancer: PET/CT.
Bring copies of scan reports, pathology and blood results, and a list of every medicine and supplement.
The treatments I may be offered
- Tis or T1a with a clear cystic duct margin: No further surgery; the simple cholecystectomy is treatment enough. (Simple cholecystectomy, Cystic duct margin)
- T1b, T2 or T3, no metastases: Referral to a hepatobiliary centre; interval CT or MRI and PET-CT; radical cholecystectomy (liver bed plus portal lymphadenectomy) at 4 to 8 weeks, with bile duct resection only for a positive cystic duct margin; port sites not routinely excised; adjuvant capecitabine after. (Radical (extended) cholecystectomy, Segment IVb and V liver resection (versus wedge resection), Lymphadenectomy (lymph node dissection), Cystic duct margin, Port-site metastasis, PET/CT, Capecitabine, BILCAP)
- Residual disease found on interval imaging or at re-operation: Systemic treatment as for advanced gallbladder cancer. (Gemcitabine + cisplatin, Durvalumab, Pembrolizumab)
From the standard of care recorded for this cancer; which apply depends on your stage and biomarkers. Ask which the team recommends and why.